Company / SG&A Expense
Esperion Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$165.8M
FY2025
5-year range
$109.1M / $185.0M
FY2021-FY2025
Trend
+1.7%
vs FY2024
Sector context
#84 of 213
Health Care
What the data says
At $166M, Esperion Therapeutics, Inc.'s sg&a expense ranks #130 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $109M in FY2022 to $166M in FY2025.
Based on SEC 10-K filings.
$166M in FY2025 with a 5-year CAGR of -3.6%.
Increased from $143M to $166M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.0%
- 5-Year CAGR
- -3.6%
- 10-Year CAGR
- -
Sector benchmark
#130 of 213 in Health CareTop 61% of 213This company $165.8M Sector average $722.3M
▼
-77.0% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of -3.6%, indicating a declining trend.
- In FY2025, sg&a expense increased 1.7% year-over-year.
- Ranks #84 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $165.8M | +1.7% |
| FY2024 | $163.1M | +14.4% |
| FY2023 | $142.5M | +30.7% |
| FY2022 | $109.1M | -41.0% |
| FY2021 | $185.0M | -7.3% |
| FY2020 | $199.6M | +203.1% |
| FY2019 | $65.9M | +99.0% |
| FY2018 | $33.1M | +54.8% |
| FY2017 | $21.4M | +16.9% |
| FY2016 | $18.3M | -9.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026